IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer  by Greten, Florian R. et al.
Cell, Vol. 118, 285–296, August 6, 2004, Copyright 2004 by Cell Press
IKK Links Inflammation and Tumorigenesis
in a Mouse Model of Colitis-Associated Cancer
and around tumors contains cells of the innate immune
system that secrete proinflammatory cytokines and che-
mokines, such as TNF, IL-1, IL-6, and IL-8, as well as
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pathways that affect cell proliferation and/or survival
(Coussens and Werb, 2002). However, it is usually envi-
sioned that inflammation stimulates the formation ofSummary
epithelial-derived tumors, the most common class of
cancers, through an indirect mechanism involving acti-A link between inflammation and cancer has long been
vation of surrounding inflammatory cells (Balkwill andsuspected, but its molecular nature remained ill de-
Mantovani, 2001). The interplay between epithelial cellsfined. A key player in inflammation is transcription
and inflammatory cells is likely to be a crucial, but poorlyfactor NF-B whose activity is triggered in response
understood, process during inflammation-associatedto infectious agents and proinflammatory cytokines
tumor development.via the IB kinase (IKK) complex. Using a colitis-asso-
A key player in inflammatory processes is transcrip-ciated cancer model, we show that although deletion
tion factor NF-B (Barnes and Karin, 1997; Chen et al.,of IKK in intestinal epithelial cells does not decrease
2003), which consists of a number of closely relatedinflammation, it leads to a dramatic decrease in tumor
protein dimers that bind a common sequence motifincidence without affecting tumor size. This is linked
(Ghosh et al., 1998). In resting, nonstimulated cells NF-to increased epithelial apoptosis during tumor promo-
B dimers are cytoplasmic but translocate to the nu-tion. Deleting IKK in myeloid cells, however, results
cleus in response to a variety of proinflammatory stimuli.in a significant decrease in tumor size. This deletion
Two major pathways account for nuclear translocation
diminishes expression of proinflammatory cytokines
(i.e., activation) of NF-B. The canonical NF-B activa-
that may serve as tumor growth factors, without af- tion pathway, applies to dimers composed of RelA,
fecting apoptosis. Thus, specific inactivation of the c-Rel, and p50, which are retained in the cytoplasm by
IKK/NF-B pathway in two different cell types can at- specific inhibitors, the IB proteins (Ghosh and Karin,
tenuate formation of inflammation-associated tumors. 2002). This pathway is normally triggered in response
In addition to suppressing apoptosis in advanced tu- to microbial and viral infections and proinflammatory
mors, IKK may link inflammation to cancer. cytokines all of which activate the IB kinase (IKK) com-
plex (Ghosh and Karin, 2002). IKK phosphorylates NF-
Introduction B bound IBs and targets them for ubiquitin-dependent
degradation and allowing liberated NF-B dimers to en-
For about two millennia, a causal relationship between ter the nucleus (Karin and Ben-Neriah, 2000). IB phos-
inflammation and cancer has been suspected. It was phorylation depends mainly on the IKK catalytic sub-
Galen who first noted this relationship and later in the unit of the IKK complex (Li et al., 1999a, 1999b). The
19th century Rudolf Virchow had demonstrated the pres- second pathway, the alternative pathway, depends on
ence of leukocytes in malignant tissues and claimed processing of the NF-B2 precursor protein, which pref-
that tumors arise from regions of chronic inflammation erentially binds RelB in the cytoplasm, resulting in re-
(Balkwill and Mantovani, 2001). The microenvironment in lease of RelB:p52 dimers (Ghosh and Karin, 2002). This
pathway depends on the IKK subunit (Senftleben et
al., 2001) and is IKK-independent (Dejardin et al., 2002).*Correspondence: karinoffice@ucsd.edu
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Both pathways ultimately lead to transcription of distinct cell types where NF-B is activated during colitis and
sets of target genes, mediating different biological func- CAC, namely enterocytes and macrophages, could pre-
tions. vent tumor initiation and progression in a mouse model
The involvement of the canonical IKK/NF-B activa- of CAC (Okayasu et al., 1996). We show that inactivation
tion pathway in acute inflammation and cell survival is of IKK in either cell type can indeed reduce the inci-
well established (Chen et al., 2003; Maeda et al., 2003). dence and development of inflammation-associated
In addition to inflammation, persistent NF-B activation cancer, but in each cell type IKK acts through a differ-
was suggested to contribute to cancer (Karin et al., ent mechanism. While in enterocytes IKK contributes
2002). Chromosomal rearrangements leading to consti- to tumor initiation and promotion by suppressing apo-
tutive NF-B activation or overexpression of NF-B sub- ptosis, but is not required for inflammation per se, in
units were detected in lymphoid malignancies (Gilmore, myeloid cells it is involved in production of inflammatory
1999; Hacker and Karin, 2002). Activated NF-B was mediators that promote tumor growth.
also detected in many solid tumors and its inhibition in
tumor cell lines increases their sensitivity to chemother- Results
apeutic drugs and radiation (Amit and Ben-Neriah,
2003). The latter effect is related to the known ability of Deletion of IKK in Enterocytes Greatly Decreases
NF-B to activate genes whose products inhibit apopto- Colitis-Associated Tumor Incidence
sis (Karin and Lin, 2002), which could be instrumental Azoxymethane (AOM) is a procarcinogen, which upon
in tumor development. So far, however, the role of NF-B metabolic activation causes formation of O6-methyl-
in the initiation of solid tumors has not been examined, guanine (Pegg, 1984). AOM induces tumors in the distal
except for skin tumors, where inhibition of NF-B was colon of rodents and is commonly used to elicit colo-
found to promote squamous cell carcinomas (Dajee et rectal cancer in experimental animals (Boivin et al.,
al., 2003; Seitz et al., 1998; van Hogerlinden et al., 1999). 2003). To investigate the role of IKK in CAC, we used
Yet, the ability of NF-B to be activated by proinflamma- a model in which 6–8-week-old mice were injected with
tory stimuli and in turn inhibit apoptosis led us to pro- a single dose of AOM (12.5 mg/kg) followed by three
pose that the canonical IKK-NF-B pathway may pro- cycles of dextran sulfate sodium salt (DSS) administra-
vide the critical mechanistic link between inflammation tion (cycle 1: 2.5%, five days; cycle 2: 2.5%, five days;
and cancer (Karin et al., 2002). and cycle 3: 2%, four days) in the drinking water (Figure
Activation of NF-B in response to chronic inflamma- 1A). Repeated DSS administration causes chronic in-
tion may be of particular relevance to gastrointestinal flammation, thereby mimicking IBD, which greatly en-
(GI) carcinogenesis, especially in gastric cancer and co- hances the incidence of AOM-induced tumors (Okayasu
litis-associated cancer (CAC). The latter arises in pa- et al., 1996).
tients with inflammatory bowel disease (IBD), particu- This protocol was applied to mice that lack IKK only
larly ulcerative colitis. CACs comprise up to 5% of all in their intestinal epithelial cells (villin-Cre/IkkF/ mice)
colorectal cancers (Chung, 2000). The cumulative inci- (Chen et al., 2003) and their littermate controls (IkkF/
dence of CAC in patients with ulcerative colitis 25–30
mice). Previous results indicate that deletion of IKK in
years after diagnosis ranges from 8% to 43% (Ekbom,
enterocytes does not perturb normal gastrointestinal
1998), accounting for one sixth of all deaths in this group
development or function in nonchallenged mice and has(Munkholm, 2003). Anti-inflammatory therapy with non-
no effect on tissue composition or body weight (Chensteroidal anti-inflammatory drugs (NSAIDs) reduces the
et al., 2003; Egan et al., 2004). Regardless of genotype,risk of CAC by 75% to 81% (Eaden et al., 2000). NSAIDs
all mice treated with AOM plus DSS developed tumors,were reported to inhibit the IKK-dependent NF-B-
whereas mice receiving DSS alone without AOM did notsignaling pathway (Kopp and Ghosh, 1994; Yamamoto
develop tumors during the observation period (data notet al., 1999; Yin et al., 1998), in addition to their known
shown). We observed a dramatic decrease of 75% inability to inhibit cyclooxygenases (COX) and prostaglan-
tumor incidence in the IKK knockout group (Figure 1B).din synthesis (Gupta and Dubois, 2001). Activated NF-
These tumors were located in the middle to distal colonB was detected in lamina propria macrophages and
(Figures 1C and 1D), which is the area where the mostepithelial cells from biopsy specimens or cultured cells
severe changes during DSS colitis occur (Okayasu etof IBD patients (Rogler et al., 1998) as well as in colo-
al., 1990), suggesting that the severity of inflammationrectal and cancer but not in adjacent normal tissue (Lind
correlates with increased tumor incidence. The tumorset al., 2001; Yu et al., 2003). Moreover, in human sporadic
were mostly broad-based adenomas with high-gradecolonic adenomatous polyps, RelA was detected in nu-
dysplasia and varying degree of inflammatory cell infil-clei of stromal macrophages that also expressed certain
tration (Figures 1E–1J). Adenomas did not penetrate theNF-B target genes, including COX-2 (Hardwick et al.,
muscularis mucosa in any of the groups. Even though2001). COX-2 expression in tumor-infiltrating macro-
the tumors resemble histologically those that appear inphages is an early event in colon carcinogenesis and
ApcMin/ mice, which are also rarely invasive, the latterinhibition of COX-2 activity represents an effective
are mainly localized to the small intestine (Moser etchemopreventive strategy (Janne and Mayer, 2000).
al., 1990). Since AOM leads to induction of mutationsAlthough the evidence for potential involvement of
throughout the whole intestine, it is likely that the inflam-NF-B in colitis and colorectal cancer is quite substan-
mation, which is localized to the large intestine, is crucialtial, a direct genetic proof of its role in tumor initiation
for tumorigenesis in the AOM-DSS model. No significantand promotion was heretofore not available. We exam-
ined whether tissue-specific deletion of IKK in the two differences in sizes, proliferation index, or apoptotic in-
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Figure 1. Enterocyte-Specific Deletion of IKK Decreases Tumor Incidence
(A) Schematic overview of the CAC model; each rectangle represents one week. After initial AOM injection (12.5 mg/kg), DSS was given in
drinking water (gray areas) followed by regular water.
(B) Tumor incidence in IkkF/ and villin-Cre/IkkF/ mice (n  9, p  0.001)
(C–J) H&E stainings of tumor morphology.
(C and D) Overview of representative sections of the “Swiss-rolls” that were used for tumor counting. Tumors are marked by black lines.
(E and F) Representative tumors, lines mark borders between adenomas (T) and normal epithelium, 40 magnification.
(G and H) Adenomas show infiltration with inflammatory cells and ulceration on the luminal surface, 100 magnification
(I and J) Nuclei of adenomas (T) show pseudostratification and increased mitotic figures relative to normal tissue (N), 400 magnification.
(K and L) Tumor apoptotic and proliferation indices were determined by TUNEL and BrdU staining, respectively.
(M) Histogram showing size distribution of tumors. Tumor areas were determined by computerized image analysis.
dex between tumors in villin-Cre/IkkF/ mice or control they clearly had a premalignant phenotype. We also
analyzed the tumors for the presence of p21, p53, andIkkF/ mice could be detected at nine weeks after tumor
initiation (Figures 1K–1M). COX-2 by immunohistochemistry. While in both geno-
types strong nuclear staining for p21 was detectedMutations in the APC or -catenin gene that lead to
stabilization of -catenin and transcriptional activation within the tumors, only very few infiltrating cells were
COX-2 positive (data not shown). None of the tumorswith TCF-4 are very important events in colorectal carci-
nogenesis (Morin et al., 1997). We therefore used laser was p53 positive, suggesting that they did not harbor
mutant p53 alleles (data not shown).capture microdissection to isolate tumor tissue and pre-
pare genomic DNA that was analyzed for mutations in To examine the possibility that tumors in villin-Cre/
IkkF/ mice arose from cells that had escaped IKKexon 3 of the -catenin gene. Independent of genotype,
we found various mutations around the GSK-3 phos- deletion, we analyzed deletion of the floxed allele in DNA
from microdissected tumors. At least 8 out of 10 tumorsphorylation sites of -catenin (Figure 2A). Activation of
the -catenin/TCF-4 pathway was further confirmed by contained the deleted allele (Figure 2H). However, 1 or
2 of the tumors contained higher levels of the nondeletedimmunohistochemistry showing a shift of -catenin from
the membrane where it is present in untransformed epi- “floxed” allele, suggesting they arose from cells in which
the “floxed” IkkF-allele was not yet deleted. Thus, thethelium toward a cytoplasmic and nuclear pattern in the
tumors (Figures 2B and 2C). This was accompanied with decrease in tumor incidence caused by deletion of IKK
may be close to 80%. Given that normal enterocytesnuclear accumulation of two-catenin target gene prod-
ucts c-Myc and cyclin D1 (Figures 2D–2G). In normal from villin-Cre/IkkF/ mice do not express any IKK
(Chen et al., 2003), these results suggest that the fewtissue, nuclear c-Myc and cyclin D1 were restricted to
a few proliferating cells at the base of colonic crypts. cells within the colonic crypts, which are yet to experi-
ence IKK deletion, may be preferentially transformed.Even though the observed tumors were not invasive,
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Figure 2. Tumors Harbor -Catenin Muta-
tions and Exhibit Activation of the -Cate-
nin Pathway
(A) Mutations within exon 3 of the -catenin
gene. DNA was eluted from microdissected
tumor cells. Exon 3 that codes for the GSK-
3 phosphorylation sites (boxed exons) was
amplified and sequenced. Codons containing
mutations are in bold.
(B and C) Activation of -catenin. Immunohis-
tochemical analysis of -catenin in normal
epithelium (B) and in tumors (C).
(D and E) Immunhistochemical analysis of
c-Myc in normal epithelium (D) and in tu-
mors (E).
(F and G) Immunohistochemical analysis of
Cyclin D1 in normal epithelium (F) and in tu-
mors (G).
(H) Analysis of IKK deletion in tumor DNA.
DNA from microdissected normal epithelium
of villin-Cre/IkkF/ mice (a), normal epithe-
lium and tumors from IkkF/ mice (b) and from
tumors of villin-Cre/IkkF/ mice (c) was ana-
lyzed by PCR for deletion of Ikk exon 3. Ct
values were obtained by subtracting Ct values
of two other genes not affected by the dele-
tion from the Ikk Ct values
Given the large reduction in tumor incidence but no mice lost significantly more weight than littermate con-
apparent effect on tumor size or growth, these results trols (Figure 3A) and showed a significantly higher level
suggest that within enterocytes IKK is mostly important of histological damage and greater ulcer numbers (Fig-
during early stages of tumor initiation and/or promotion. ures 3B and 3C). Representative histological sections
are shown in Figures 3D–3G.
Despite the insignificant increases in histological in-Enterocyte-Specific Deletion of IKK Does Not
flammation, the colons of villin-Cre/IkkF/ mice exposedPrevent DSS-Induced Inflammation
to 2.5% DSS contained higher levels of mRNAs for proin-Inhibition of NF-B activation is associated with reduced
flammatory proteins, such as TNF, IL-1, ICAM, IL-6,colonic inflammation and both RelA antisense oligonu-
as well as the mouse IL-8 homologs MIP-2 and KC (Fig-cleotides and IKK inhibitors were found to attenuate
ure 4A). DSS-treated villin-Cre/IkkF/ mice also exhib-the course of colitis (MacMaster et al., 2003; Murano et
ited elevated expression of COX-2 and matrix metallo-al., 2000). To test whether reduced colonic inflammation
protease 9 (Figure 4B). These proteins, however, arein villin-Cre/IkkF/ mice is responsible for the observed
expressed in myeloid rather than epithelial cells (seedifferences in tumor incidence, we evaluated the out-
below). Collectively, these results indicate that the re-come of acute and chronic colitis in villin-Cre/IkkF/
duced tumor incidence in villin-Cre/IkkF/ mice is notmice and their littermate controls. No differences in clini-
due to reduced inflammation. Since DSS is believed tocal signs (i.e., weight loss, diarrhea, or rectal bleeding)
induce colonic inflammation through physical disruptionor colon histology could be detected between the two
of the mucosal barrier function thus exposing innategroups after completion of the nine-week CAC regimen
immune cells in the lamina propria to bacteria or bacte-(data not shown). However, at day 15 of the CAC regimen
rial products (Okayasu et al., 1990), the increased inflam-(i.e., five days after termination of the first DSS cycle)
mation in villin-Cre/IkkF/ mice is most likely due tovillin-Cre/IkkF/ mice exhibited a slightly higher level of
decreased epithelial cell survival (see below). We alsohistological damage that was not statistically significant
examined whether the loss of IKK in enterocytes af-(data not shown). We therefore increased the concentra-
fected the proliferation of the epithelial cells in responsetion of DSS (from 2.5% to 3.5%) to induce a more acute
inflammation. Under these conditions villin-Cre/IkkF/ to the inflammatory challenge. However, no significant
IKK in Colonic Tumor Development
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may also induce more apoptosis in villin-Cre/IkkF/
mice. However, AOM (without DSS) acted differently
from 	-radiation and did not lead to increased apoptosis
in the IKK-deleted mice (data not shown). In accor-
dance with published results (Toft et al., 1999), the AOM-
triggered apoptotic response was almost completely
abolished in p53
/
 mice (data not shown). These results
rule out the possibility that villin-Cre/IkkF/ mice had
decreased tumor numbers due to differences in the ini-
tial response to the carcinogen.
As mentioned above, one of the mechanisms by which
DSS leads to development of colitis is induction of epi-
thelial apoptosis. Epithelial apoptosis was also reported
in ulcerative colitis patients, leading to inflammation of
the colonic mucosa due to loss of barrier function (Iwa-
moto et al., 1996). We used terminal deoxynucleotidyl
transferase-mediated dUTP nick-end-labeling (TUNEL)
to examine the DSS-induced apoptotic response in AOM
treated or nontreated mice. A high dose of oral DSS
(3.5%) induced clusters of TUNEL-positive cells within
the surface epithelium of the middle and distal colon,
consistent with the greater tissue damage. The areas
containing apoptotic cells were significantly larger in
villin-Cre/IkkF/ mice relative to littermate controls (data
not shown). However, exposure to a lower concentration
of DSS (2.5%) during the CAC regime resulted in more
extensive and uniform epithelial apoptosis than caused
by DSS alone. In this case, the difference between villin-
Cre/IkkF/ mice and their IkkF/ littermate controls was
quite striking (Figures 5A and 5B). Surprisingly, however,
at day 7 of the CAC regimen p53
/
 mice did not show
decreased enterocyte apoptosis relative to littermate
controls that were exposed to the CAC regimen (data
not shown), suggesting the involvement of a p53-inde-
pendent mechanism.
Biochemical analysis of isolated enterocytes seven
days after initiation of the CAC regimen confirmed that
exposure to AOM and DSS led to IKK activation (Figure
Figure 3. Increased Colonic Inflammation in villin-Cre/IkkF/ Mice 5C). No IKK activity was detected in villin-Cre/IkkF/
Challenged with High Levels of DSS epithelial cells. Immunoblot analysis of anti- and proapo-
(A) Weight loss during DSS (3.5%) colitis in IkkF/ and villin-Cre/ ptotic proteins showed marked induction of Bcl-xL inIkkF/ mice.
IkkF/ mice that was absent in villin-Cre/IkkF/ mice.(B) Histological damage (n  7, p  0.05) and (C) ulcer number
By contrast, the levels of the proapoptotic proteins Bak(n  7, p  0.05) in mice treated with 3.5% DSS.
and Bax were slightly higher in villin-Cre/IkkF/ mice.(D) Histology of untreated IkkF/ and (E) and untreated villin-Cre/
IkkF/ mice. Representative histologies of (F) IkkF/ mice and (G) This perturbance in expression of Bcl-2 family members
villin-Cre/IkkF/ mice five days after the termination of DSS adminis- could account for the increased apoptosis in the knock-
tration. out mice. No upregulation of p53, Mdm2, or p21 was
detected in enterocytes of either genotype (data not
shown). No changes in JNK activity could be detected
difference in BrdU incorporation into colonic epithelial between the two genotypes (Figure 4C) suggesting that
cells of mice given 2.5% DSS could be detected be- sustained JNK activation (Maeda et al., 2003; Tang et
tween the two genotypes (Figures 4C and 4D). al., 2001) is not responsible for the increase in epithelial
apoptosis in AOMDSS treated villin-Cre/IkkF/ mice.
Loss of IKK in Epithelial Cells Results
in Enhanced p53-Independent Apoptosis Deletion of IKK in Myeloid Cells Decreases
Tumor Growth without an Effect on Apoptosisduring Early Tumor Promotion
Alkylating agents, such as AOM, induce rapid p53- To address the role of the IKK-dependent NF-B path-
way in myeloid cells, we crossed LysM-Cre mice (Clausendependent apoptosis of epithelial cells in the lower one
third of the intestinal crypt (Toft et al., 1999). Previously et al., 1999) with IkkF/F mice and generated mice that
specifically lack IKK in the myeloid lineage. Analysiswe found increased radiation-induced apoptosis asso-
ciated with increased p53 expression in the small intes- of DNA of bone-marrow-derived macrophages (BMDM)
obtained from LysM-Cre/IkkF/F mice by real-time PCRtine of villin-Cre/IkkF/ mice relative to IkkF/ controls
(Egan et al., 2004). We therefore examined whether AOM revealed a deletion efficiency of around 75% in these
Cell
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Figure 4. Increased Expression of Proinflam-
matory Factors during DSS-Colitis in villin-
Cre/IkkF/ Mice
(A) Expression of inflammatory genes. Rela-
tive mRNA expression levels were examined
in whole colon tissues of mice at day 15 of
the CAC regimen, 5 days after DSS (2.5%).
The levels of the indicated mRNAs were
quantitated by real-time PCR and normalized
to the level of cyclophilin mRNA (n  3).
(B) NF-B binding activity, COX-2 and MMP-9
expression in whole colonic extracts pre-
pared at days 0 and 15 of the CAC regimen
five days after DSS (2.5%) challenge. NF-B
binding activity was determined by EMSA.
COX-2 and MMP-9 expression were deter-
mined by Western blotting (WB).
(C and D) BrdU incorporation into intestinal
epithelial cells at day 15 of the CAC regimen,
five days after termination of DSS challenge.
cells. Similar results were obtained by Southern blotting proliferation indices determined at nine weeks after initi-
ation of the CAC regimen were similar in both groupsand also for neutrophils (data not shown). Immunoblot
analysis confirmed the loss of IKK expression (Supple- (Figures 6E and 6F). To examine whether the IKK dele-
tion perturbs recruitment of myeloid cells to the tumors,mental Figure S1A available at http://www.cell.com/
cgi/content/full/118/3/285/DC1), resulting in diminished we stained tumors for F4/80. We did not detect any
difference between the two genotypes (Figures 6G andNF-B activation determined by electrophoretic mobility
shift assay (Supplemental Figure S1B available on Cell 6H). To understand how IKK in myeloid cells affects
tumor development, we first compared the apoptoticwebsite). The effect of the deletion on expression of NF-
B target genes encoding proinflammatory cytokines, response to AOM, AOM plus DSS, or DSS alone in LysM-
Cre/IkkF/F and IkkF/F mice. No substantial differenceschemokines, and other factors, that are known to be
involved in colitis and could potentially contribute to in the extent of apoptosis could be detected between
the two genotypes after any of the treatments (Figuretumor progression, was analyzed by real-time PCR. We
detected reduced expression of genes encoding IL-1, 7A and data not shown). No changes in Bcl-xL induction
could be observed either (Figure 7B). Thus, the lowerIL-1, IL-6, KC, MIP-2, TNF, COX-2, and ICAM (Supple-
mental Figure S1C available on Cell website). Thus, inac- tumor incidence in LysM-Cre/IkkF/F mice is not due to
accelerated loss of initiated cells, as it is the case fortivation of IKK in macrophages reduces expression of
many genes that contribute to the inflammatory re- villin-Cre/IkkF/ mice.
We then examined the effect of IKK deletion in my-sponse.
Deletion of IKK in myeloid cells also reduced tumor eloid cells on production of factors that may act in a
paracrine manner to promote tumor growth and devel-incidence in the CAC model. LysM-Cre/IkkF/F mice
showed an almost 50% reduction in tumor counts (Fig- opment. At five days after termination of the first DSS
cycle the LysM-Cre/IkkF/F mice exhibited reduced in-ure 6A). Although the tumor morphology was similar in
both genotypes (Figures 6B and 6C), the LysM-Cre/ duction of the mRNAs for IL-1, ICAM, IL-6, as well as
MIP-2 and KC (Figure 7C). Unlike the enterocyte-specificIkkF/F mice exhibited a greater percentage of smaller
tumors than IkkF/F mice (Figure 6D). The apoptotic and deletion, which resulted in increased COX-2 and MMP-9
IKK in Colonic Tumor Development
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the other proinflammatory mediators, are expressed by
myeloid cells.
To address whether the decreased expression of pro-
inflammatory factors might affect inflammation induced
epithelial proliferation we analyzed BrdU incorporation
in mice of both genotypes at 15 days after AOM plus
DSS treatment. We detected a substantial difference in
proliferating epithelial cells, which were present in areas
that exhibited extensive histological inflammation in
LysM-Cre/IkkF/F mice compared to littermate controls
(Figures 7E and 7F). These data support the notion that
IKK in myeloid cells can promote tumor growth and
development through production of tumor-promoting
paracrine factors, rather than inhibition of tumor cell
apoptosis.
As inhibition of COX-2 is an accepted chemopreven-Figure 5. Massive Apoptosis and Defective Bcl-xL Induction in Co-
tive strategy (Gupta and Dubois, 2001), we tested thelonic Epithelium of villin-Cre/IkkF/ Mice
effect of COX-2 inhibition on the early apoptosis in our(A and B) TUNEL stainings of colons of IkkF/ and villin-Cre/IkkF/
model as well as on the proliferation of enterocytes.mice at day 7 after administration of AOM, two days after beginning
of DSS (2.5%) exposure. Wild-type mice were injected twice daily with the spe-
(C) Biochemical analysis of enterocytes isolated from mice at day cific COX-2 inhibitor NS-398 starting one day before
7 of the CAC regimen. KA: Kinase assay; WB: Western blot analysis. the AOM administration. However, no differences in the
extent of apoptosis on day 7 of the regimen could be
detected (Supplemental Figures S2A and S2B available
induction, the myeloid-specific deletion of IKK resulted on Cell website). Mice treated with NS-398 showed a
in a substantial decrease in expression of both proteins more severe form of acute colitis characterized by
after DSS treatment (Figure 7D). These results strongly greater weight loss and tissue damage on day 15 (Sup-
plemental Figures S2C and S2D available on Cell web-suggest that both of these proteins, as well as most of
Figure 6. Myeloid-Specific Deletion of IKK
Decreases Tumor Incidence and Growth
(A) Tumor incidence in IkkF/F and LysM-Cre/
IkkF/F mice (n  7, p  0.03).
(B–F) Tumor characteristics: (B and C) repre-
sentative sections stained with H&E of tumors
from both genotypes showing decreased tu-
mor size in LysM-Cre/IkkF/F mice; (D) Tumor
size distribution determined as for Figure 1M.
(E and F) Tumor apoptotic and proliferative
indices, determined as described in Figures
1K and 1L.
(G and H) Staining of tumor sections with anti-
F4/80 antibody to reveal infiltrating myeloid
cells.
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Figure 7. Myeloid-Specific Deletion of IKK Does Not Affect Early Apoptosis but Reduces Expression of Potential Tumor-Promoting Factors
and Enterocyte Proliferation
(A) TUNEL staining of colons of IkkF/F mice and LysM-Cre/IkkF/F mice at day 7 of the CAC regimen.
(B) Western blot analysis of Bcl-xL levels in whole colonic extracts of the same mice.
(C) Relative mRNA expression levels in whole colons of mice on day 15 of the CAC regimen. The levels of the indicated mRNAs were quantitated
by real-time PCR and normalized to the level of cyclophilin mRNA (n  3).
(D) COX-2 and MMP-9 levels in whole colonic extracts of mice on day 15 of the CAC regimen.
(E and F) BrdU incorporation into epithelial cells determined on day 15 of the CAC regimen.
site, and data not shown), but there was no apparent While probing the role of IKK in linking inflammation
and cancer, we also investigated in which cell type it isdifference in the number of BrdU-labeled cells within
areas of inflammation on day 15 (Supplemental Figures most likely to act. Our results indicate that IKK acts
both within enterocytes, which eventually give rise toS2E and S2F available on Cell website). The COX-2 in-
hibitor, however, was effective in reducing prostaglan- the transformed component of the tumor, and within
myeloid cells, which influence tumor growth. In eachdin synthesis (Supplemental Figure S2G available on
Cell website). The failure to observe an ameliorating cell type IKK contributes to tumor promotion through
a different mechanism. Our results strongly suggest thateffect of the COX-2 inhibitor on inflammation in this
model is consistent with findings in COX-2 deficient in epithelial cells IKK contributes to tumor promotion
by suppressing apoptosis through the mitochondrialmice (Morteau et al., 2000).
pathway. IKK in these cells is required for induction of
Bcl-xL, which is encoded by a typical NF-B target geneDiscussion
(Chen et al., 2000). The absence of IKK in enterocytes
prevents Bcl-xL induction and leads to increased apo-A connection between inflammation and cancer has
been suspected for a long time. It has become apparent ptosis of carcinogen-exposed cells a few days after
administration of the tumor promoter (DSS). As the re-that the interaction between transformed cells and their
close surrounding, including innate immune cells, fibro- sults clearly demonstrate, the reduced tumor incidence
in villin-Cre/IkkF/ mice is not due to a decreased inflam-blasts, and endothelial cells, can be instrumental in both
tumor promotion and progression of many epithelial tu- matory response. Thus, IKK in enterocytes plays a criti-
cal and direct role in tumor promotion, which is distinctmors, especially in the context of chronic inflammation
(Balkwill and Mantovani, 2001; Coussens and Werb, from its role in expression of inflammatory mediators, a
function exerted mainly within myeloid cells in this2002). However, the underlying molecular processes in-
volved in this interaction are still poorly understood. We model. A more modest, yet significant, reduction in tu-
mor incidence is obtained by deleting IKK in myeloidnow show that the IKK-dependent NF-B activation
pathway represents a critical molecular link between cells. This deletion has no effect on either the expression
of Bcl-xL or the apoptotic response of carcinogen-inflammation and cancer in a mouse model of CAC.
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exposed cells. Instead, the deletion of IKK in myeloid factors, rather than affecting the very early stages of
the tumorigenic process.cells results in a marked decrease in inflammation-
This report provides one of the few examples thatinduced proliferation of enterocytes and tumor size, indi-
inactivation of a gene encoding a protein that is notrect effects that were not seen with the enterocyte-
directly involved in the autonomous control of cell prolif-specific deletion. Congruently, IKK in myeloid cells is
eration can dramatically reduce tumor development. Ab-required for expression of proinflammatory factors, such
lations of cyclin D1 and c-Jun were shown to reduce theas COX-2, MMP-9, KC, and MIP-2, all of which are be-
incidence of mammary and hepatocellular carcinomas,lieved to contribute to tumor growth (Coussens and
respectively (Eferl et al., 2003; Yu et al., 2001). Yet, bothWerb, 2002).
cyclin D1 and c-Jun are critical regulators of cell prolifer-Activated NF-B was detected in many different tumor
ation in the mammary gland and liver, thus, the reduc-cell lines and primary tumor samples (Barkett and Gil-
tions in tumor incidence caused by their deletion aremore, 1999), but until now it was not clear whether NF-
somewhat expected. Regarding colon cancer, the mostB is instrumental for tumor initiation and promotion.
striking results were obtained with COX-2 knockoutNonetheless, it is well accepted that inhibition of NF-
mice (Oshima et al., 1996), results that supported theB activity in cancer cells can lead to increased sensitiv-
successful chemoprevention studies in familial adeno-ity to chemo- and radiotherapy (Amit and Ben-Neriah,
matous polyposis (FAP) patients (Steinbach et al., 2000).2003). In the CAC model, which combines chemical car-
Like IKK, COX-2 is an important mediator of inflamma-cinogenesis and inflammation, we wanted to determine
tion and does not directly control cell proliferationthe role of IKK in initiation and early tumor promotion
(Gupta and Dubois, 2001).rather than the response of cancer cells to therapy.
Evading apoptosis is one of the hallmarks of cancerGiven the broad range of genes that NF-B can regulate,
(Hanahan and Weinberg, 2000) and induction of apopto-including genes that have immunoregulatory and proin-
sis during tumor promotion represents a critical step forflammatory functions, as well as genes that either inhibit
chemoprevention. Upregulation of Bcl-xL during tumoror promote apoptosis (Karin et al., 2002), one can envi-
promotion seems important in both CAC and sporadicsion that in certain cell types NF-B activation may pro-
colorectal cancer (Yu et al., 2003). One way to avoidmote tumor development while in other cases it may
upregulation of Bcl-xL and thereby promote the elimina-inhibit tumorigenesis. Indeed, it was found that inhibition
tion of initiated cells may entail inhibition of IKK. Inter-of NF-B in keratinocytes promotes development of
estingly, several NSAIDs used in chemoprevention ofsquamous cell carcinomas in human and mouse models
colorectal cancer, such as sulindac, can act as IKK(Dajee et al., 2003; Seitz et al., 1998; van Hogerlinden
inhibitors (Yamamoto et al., 1999; Yin et al., 1998). Theet al., 1999, 2002). We have also detected a similar in-
chemopreventive activity of NSAIDs has been explainedcrease in tumor incidence in mice lacking IKK in hepa-
by three different mechanisms. The most widely ac-tocytes (Maeda et al., 2003) using a chemical carcino-
cepted explanation is inhibition of COX-2 activity (Guptagenesis model that does not involve inflammation as
and Dubois, 2001). The second proposed mechanisma tumor promoter (M.K. et al., unpublished data). The
entails inhibition of PPAR, which lead to induction ofpresent findings, however, show for the first time that
apoptosis in colorectal cancer cell lines (He et al., 1999).in a model that involves inflammation as a tumor pro-
NSAIDs can also stimulate PPAR	, which was shownmoter NF-B activation can enhance tumor develop-
to inhibit intestinal tumor development (Girnun et al.,ment and underscore the importance of using condi-
2002). The third putative mechanism entails inhibitiontional knockout mice and different models of cancer to
of IKK, as suggested by our results that genetic abla-determine the full pathophysiological function of a given
tion of IKK can reduce the incidence of CAC. Using asignaling pathway. Interestingly, the inhibition of IKK in
highly specific COX-2 inhibitor, at a dose that does notkeratinocytes and enterocytes also results, in diametri-
inhibit IKK, we failed to detect increased enterocyte
cally opposed effects on inflammation. While deletion
apoptosis in mice subjected to the CAC regimen.
of IKK in enterocytes reduced acute inflammation
The role of macrophages in tumor development in
caused by gut ischemia-reperfusion and mediated by contrast to tumor progression has not been clearly es-
TNF (Chen et al., 2003), its deletion in keratinocytes tablished, although these cells are important compo-
enhanced TNF-dependent inflammation (Pasparakis et nents of the tumor microenvironment (Balkwill and Man-
al., 2002). tovani, 2001; Coussens and Werb, 2002). Elimination of
The tumors that arise from IKK-deficient enterocytes macrophages using a CSF-1 null mutation illustrated
were indistinguishable from those that form in control that macrophage recruitment is important for progres-
mice, despite the large decrease in tumor incidence and sion of mammary gland tumors, since invasive growth
contained a similar spectrum of -catenin mutations. and metastasis were significantly attenuated (Lin et al.,
This points to an important function for IKK in entero- 2001). Furthermore, it was shown that bone-marrow-
cytes during very early tumor promotion and suggests derived cells supply MMP-9 during skin carcinogenesis,
it may be dispensable for tumor maintenance and pro- and that the proliferation of transformed cells was af-
gression once the few tumors that arise in villin-Cre/ fected by factors derived from surrounding cells (Cous-
IkkF/ mice have formed. Interestingly, the deletion of sens et al., 2000). Instead of preventing CSF-1 expres-
IKK in myeloid cells had a more pronounced effect on sion, which might also affect neoplastic cells, we chose
tumor size than on tumor number. This and the effect to inactivate a specific-signaling pathway in myeloid
on the proliferative response to the tumor promoter DSS cells, without exerting a direct effect on other cell types.
strongly suggest that IKK in myeloid cells is most likely Our findings establish for the first time the role of myeloid
cells in inflammation-associated tumor promotion in ad-involved in promoting tumor growth through paracrine
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RNA, and proteins were extracted as described (Park et al., 2002).dition to their role in tumor progression and invasive-
Deletion efficiency of the floxed allele was determined by real-timeness. Since NF-B activation accounts for increased
PCR as described above. For quantification of mRNA levels beforetranscription of several hundred genes, the observed
and after LPS stimulation, real-time PCR was performed as de-
effect is likely to be due to decreased expression of scribed (Senftleben et al., 2001). Primer sequences are available
several genes, whose products enhance tumor develop- upon request.
ment, rather than a single one. Indeed, selective inhibi-
Isolation of Intestinal Epithelial Cellstion of COX-2 did not have an effect on either the apopto-
Colons were cut open longitudinally and feces was removed by briefsis or proliferation of enterocytes in mice exposed to
washing with PBS. Colons were then cut into 2–3 mm pieces andAOM and DSS. Other genes, which probably include KC
carefully rocked in Hanks’ balanced salt solution (HBSS) containing
and MIP-2, have been shown to have growth-stimulating 30 mM EDTA for 10 min at 37C. The supernatant was removed and
effects on epithelial cells (Driscoll et al., 1995). centrifuged. The resulting pellet was washed in ice-cold PBS and
In addition to identifying a key molecular mechanism pellet was snap-frozen in liquid nitrogen.
connecting inflammation and cancer, our results sug-
IKK Kinase Assay, EMSA, and Immunoblotsgest that specific pharmacological inhibition of IKK
IKK immune complex kinase assay and electrophoretic mobility shiftmay be very effective in prevention of CAC. Neverthe-
assays were performed as previously described (Cao et al., 2001).
less, given the important role of IKK in promoting innate Protein lysates were separated by SDS-gel electrophoresis and
immune responses and suppressing other types of can- transferred to PVDF membranes. The following antibodies were
cer there is a certain risk associated with long-term use used for immunoblotting as described (Senftleben et al., 2001): anti-
IKK and anti-IKK (Imgenex), anti-IB, anti-c-Myc, anti-cyclin D1,of such drugs, a problem that needs to be addressed
anti-p21, anti-p53, anti-Bak (Santa Cruz), anti--catenin (Upstate),before realizing the full benefit of IKK inhibitors in
anti-Bcl-2, anti-Bcl-xL, anti-Bax (BD PharMingen), anti-COX-2 (Cay-chemoprevention of CAC or other cancers associated
man), and anti-MMP-9 (Chemicon).
with chronic inflammation.
Statistical Analysis
Experimental Procedures Data are expressed as mean  SEM. Differences were analyzed by
Student’s t test. Values  0.05 were considered significant.
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